Training in Substance Use Disorders, Part 2: Updated Curriculum Guidelines
Can J Psychiatry. 2024 Mar 27:7067437241232456. doi: 10.1177/07067437241232456. Online ahead of print.NO ABSTRACTPMID:38533564 | DOI:10.1177/07067437241232456 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 27, 2024 Category: Psychiatry Authors: David Crockford Anees Bahji Christian Schutz Jennifer Brasch Leslie Buckley Marlon Danilewitz Simon Dubreucq Michael Mak Tony P George Source Type: research
Training in Substance Use Disorders, Part 2: Updated Curriculum Guidelines
Can J Psychiatry. 2024 Mar 27:7067437241232456. doi: 10.1177/07067437241232456. Online ahead of print.NO ABSTRACTPMID:38533564 | DOI:10.1177/07067437241232456 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 27, 2024 Category: Psychiatry Authors: David Crockford Anees Bahji Christian Schutz Jennifer Brasch Leslie Buckley Marlon Danilewitz Simon Dubreucq Michael Mak Tony P George Source Type: research
Training in Substance Use Disorders, Part 2: Updated Curriculum Guidelines
Can J Psychiatry. 2024 Mar 27:7067437241232456. doi: 10.1177/07067437241232456. Online ahead of print.NO ABSTRACTPMID:38533564 | DOI:10.1177/07067437241232456 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 27, 2024 Category: Psychiatry Authors: David Crockford Anees Bahji Christian Schutz Jennifer Brasch Leslie Buckley Marlon Danilewitz Simon Dubreucq Michael Mak Tony P George Source Type: research
Training in Substance Use Disorders, Part 2: Updated Curriculum Guidelines
Can J Psychiatry. 2024 Mar 27:7067437241232456. doi: 10.1177/07067437241232456. Online ahead of print.NO ABSTRACTPMID:38533564 | DOI:10.1177/07067437241232456 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 27, 2024 Category: Psychiatry Authors: David Crockford Anees Bahji Christian Schutz Jennifer Brasch Leslie Buckley Marlon Danilewitz Simon Dubreucq Michael Mak Tony P George Source Type: research
Training in Substance Use Disorders, Part 2: Updated Curriculum Guidelines
Can J Psychiatry. 2024 Mar 27:7067437241232456. doi: 10.1177/07067437241232456. Online ahead of print.NO ABSTRACTPMID:38533564 | DOI:10.1177/07067437241232456 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 27, 2024 Category: Psychiatry Authors: David Crockford Anees Bahji Christian Schutz Jennifer Brasch Leslie Buckley Marlon Danilewitz Simon Dubreucq Michael Mak Tony P George Source Type: research
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study
CONCLUSIONS: Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04830215.PMID:38425284 | DOI:10.1177/07067437241233965 (Source:...
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Fran çois Therrien Caroline Ward Pratap Chokka Jeffrey Habert Zahinoor Ismail Roger S McIntyre Erin M MacKenzie Source Type: research
Racial/Ethnic Disparities in Psychiatric Traits and Diagnoses within a Community-based Sample of Children and Youth
CONCLUSIONS: These results suggest a discrepancy between trait levels of OCD, ADHD and anxiety and rates of diagnoses for East Asian and South Asian youth. This discrepancy may be due to increased barriers for ethnically diverse youth to access mental health care. Efforts to understand and mitigate these barriers in Canada are needed.PMID:38425291 | DOI:10.1177/07067437241233936 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Andrew Dissanayake Annie Dupuis Christie L Burton Noam Soreni Paul Peters Amy Gajaria Paul D Arnold Russell Schachar Jennifer Crosbie Source Type: research
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study
CONCLUSIONS: Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04830215.PMID:38425284 | DOI:10.1177/07067437241233965 (Source:...
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Fran çois Therrien Caroline Ward Pratap Chokka Jeffrey Habert Zahinoor Ismail Roger S McIntyre Erin M MacKenzie Source Type: research
Racial/Ethnic Disparities in Psychiatric Traits and Diagnoses within a Community-based Sample of Children and Youth
CONCLUSIONS: These results suggest a discrepancy between trait levels of OCD, ADHD and anxiety and rates of diagnoses for East Asian and South Asian youth. This discrepancy may be due to increased barriers for ethnically diverse youth to access mental health care. Efforts to understand and mitigate these barriers in Canada are needed.PMID:38425291 | DOI:10.1177/07067437241233936 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Andrew Dissanayake Annie Dupuis Christie L Burton Noam Soreni Paul Peters Amy Gajaria Paul D Arnold Russell Schachar Jennifer Crosbie Source Type: research
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study
CONCLUSIONS: Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04830215.PMID:38425284 | DOI:10.1177/07067437241233965 (Source:...
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Fran çois Therrien Caroline Ward Pratap Chokka Jeffrey Habert Zahinoor Ismail Roger S McIntyre Erin M MacKenzie Source Type: research
Racial/Ethnic Disparities in Psychiatric Traits and Diagnoses within a Community-based Sample of Children and Youth
CONCLUSIONS: These results suggest a discrepancy between trait levels of OCD, ADHD and anxiety and rates of diagnoses for East Asian and South Asian youth. This discrepancy may be due to increased barriers for ethnically diverse youth to access mental health care. Efforts to understand and mitigate these barriers in Canada are needed.PMID:38425291 | DOI:10.1177/07067437241233936 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Andrew Dissanayake Annie Dupuis Christie L Burton Noam Soreni Paul Peters Amy Gajaria Paul D Arnold Russell Schachar Jennifer Crosbie Source Type: research
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study
CONCLUSIONS: Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04830215.PMID:38425284 | DOI:10.1177/07067437241233965 (Source:...
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Fran çois Therrien Caroline Ward Pratap Chokka Jeffrey Habert Zahinoor Ismail Roger S McIntyre Erin M MacKenzie Source Type: research
Racial/Ethnic Disparities in Psychiatric Traits and Diagnoses within a Community-based Sample of Children and Youth
CONCLUSIONS: These results suggest a discrepancy between trait levels of OCD, ADHD and anxiety and rates of diagnoses for East Asian and South Asian youth. This discrepancy may be due to increased barriers for ethnically diverse youth to access mental health care. Efforts to understand and mitigate these barriers in Canada are needed.PMID:38425291 | DOI:10.1177/07067437241233936 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Andrew Dissanayake Annie Dupuis Christie L Burton Noam Soreni Paul Peters Amy Gajaria Paul D Arnold Russell Schachar Jennifer Crosbie Source Type: research
Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study
CONCLUSIONS: Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04830215.PMID:38425284 | DOI:10.1177/07067437241233965 (Source:...
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Fran çois Therrien Caroline Ward Pratap Chokka Jeffrey Habert Zahinoor Ismail Roger S McIntyre Erin M MacKenzie Source Type: research
Racial/Ethnic Disparities in Psychiatric Traits and Diagnoses within a Community-based Sample of Children and Youth
CONCLUSIONS: These results suggest a discrepancy between trait levels of OCD, ADHD and anxiety and rates of diagnoses for East Asian and South Asian youth. This discrepancy may be due to increased barriers for ethnically diverse youth to access mental health care. Efforts to understand and mitigate these barriers in Canada are needed.PMID:38425291 | DOI:10.1177/07067437241233936 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - March 1, 2024 Category: Psychiatry Authors: Andrew Dissanayake Annie Dupuis Christie L Burton Noam Soreni Paul Peters Amy Gajaria Paul D Arnold Russell Schachar Jennifer Crosbie Source Type: research
